- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06604169
An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death
September 18, 2024 updated by: China National Center for Cardiovascular Diseases
- To observe the failure rate of S-ICD screening in HCM patients at high risk of SCD.
- To observe the incidence of IAS in HCM patients with S-ICD implantation and explore the related factors of IAS.
Study Overview
Status
Active, not recruiting
Detailed Description
The study was a multicenter, prospective, observational study that prospectively included HCM patients assessed as meeting the ICD implantation indication at Fuwai Hospital and National Collaborative Hospitals from July 1, 2024 to June 30, 2027, for pre-operation screening of S-ICD, and follow-up of patients eventually implanted with S-ICD.
Study Type
Observational
Enrollment (Estimated)
589
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100037
- Fuwai Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study was a multicenter, prospective, observational study that prospectively included HCM patients assessed as meeting the ICD implantation indication at Fuwai Hospital and National Collaborative Hospitals from July 1, 2024 to June 30, 2027.
Description
Inclusion Criteria:
- HCM patients assessed as meeting the ICD implantation indication
Exclusion Criteria:
- Combined with bradycardia with pacing indications;
- Frequent monomorphic ventricular tachycardia require ATP therapy;
- With indications of CRT;
- Combined with other diseases, life expectancy is less than 1 year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the failure rate of S-ICD screening
Time Frame: 3 months
|
S-ICD screening failed
|
3 months
|
|
The inappropriate shock event
Time Frame: 3 months
|
The incidence of inappropriate shock event
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2024
Primary Completion (Estimated)
July 31, 2027
Study Completion (Estimated)
July 31, 2028
Study Registration Dates
First Submitted
September 18, 2024
First Submitted That Met QC Criteria
September 18, 2024
First Posted (Estimated)
September 19, 2024
Study Record Updates
Last Update Posted (Estimated)
September 19, 2024
Last Update Submitted That Met QC Criteria
September 18, 2024
Last Verified
September 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Death, Sudden
- Aortic Valve Disease
- Heart Valve Diseases
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Heart Arrest
- Death
- Hypertrophy
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Death, Sudden, Cardiac
Other Study ID Numbers
- S-ICD in HCM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCM - Hypertrophic Cardiomyopathy
-
Shanghai East HospitalNot yet recruitingHCM - Hypertrophic CardiomyopathyChina
-
Rennes University HospitalRecruitingHypertrophic Cardiomyopathy (HCM)France
-
Chinese Academy of Medical Sciences, Fuwai HospitalActive, not recruitingHCM - Hypertrophic CardiomyopathyChina
-
Xijing HospitalNot yet recruiting
-
Oregon Health and Science UniversityCytokinetics; Saint Lukes Hospital Mid America Heart InstituteRecruitingHypertrophic Cardiomyopathy (HCM)United States
-
University of ManchesterNot yet recruitingHypertrophic Cardiomyopathy (HCM)United Kingdom
-
Central State Medical AcademyFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical...Enrolling by invitationHypertrophic Cardiomyopathy (HCM)Russia
-
UltraSightTerminatedEchocardiography | Hypertrophic Cardiomyopathy (HCM) | Cardiac Imaging | Obstructive Cardiomyopathy, Hypertrophic | MavacamtenUnited States
-
Tampere UniversityUniversity of Bologna; University College Dublin; University of Oxford; Rennes... and other collaboratorsActive, not recruitingHCM - Hypertrophic CardiomyopathyFinland
-
University of ManchesterRecruiting